India-US Trade Deal Unlocks Preferential Tariffs: 6 Export-Heavy Stocks Set to Benefit

India-US Trade Deal Unlocks Preferential Tariffs: 6 Export-Heavy Stocks Set to Benefit

India and the United States have signed a bilateral trade agreement that gives Indian exporters preferential tariff access to the US market, with both nations targeting $500 billion in bilateral trade. After months of punishing reciprocal tariffs that reached as high as 50% on Indian goods, this deal marks a structural shift for export-dependent companies across textiles, pharmaceuticals, specialty chemicals, and auto components.

The impact is already showing up in corporate earnings calls. Here are six companies whose filings reveal just how much they stand to gain.

Textiles: The Sector That Suffered Most, Now Bounces Back

Indo Count Industries (ICIL) — India's largest bedsheet exporter — derives roughly 70% of its core business revenue from the United States, per their Q3 FY26 earnings call, where management noted that "non-U.S. markets contribute to approximately 30% of our core business revenue." The company called the India-US trade agreement a deal that "is expected to significantly boost India's textile exports with some projections indicating a potential doubling by 2030." Indo Count has delivered a 4-year revenue CAGR of 15% and EBITDA growth CAGR of 51%, per their investor presentation. India already commands nearly 58% of US cotton sheet imports, and Indo Count leads that segment. With US subsidiaries currently operating at just 50% capacity utilization and carrying annual revenue potential of US$35 million, reduced tariffs could accelerate the ramp-up significantly. Gokaldas Exports (GOKEX) felt the tariff pain most acutely. In their FY26 earnings call, management described how a "staggering 50% US tariff on India" put the company at a disadvantage against competing Asian nations that faced only 20% reciprocal tariffs. The direct tariff impact cost INR 12-15 crores in a single quarter. Yet despite this headwind, consolidated revenue reached INR 3,915 crores with 63% year-on-year growth, and EBITDA margins improved to 12.1% from 8.8% a year ago. The company has been diversifying — the India-UK FTA offers a 12% duty advantage over China — but management acknowledged that US tariff parity with competing nations would be the biggest catalyst.

Pharma: Already Strong, Now Structurally Advantaged

Cipla has built a formidable US presence over a decade, shipping over 50 million Albuterol inhalers and holding an 18.7% TRx market share in the Albuterol segment, per their Q4 FY26 filings. North America contributes 28.1% of total revenue. The company reported US revenue of $934 million for FY25, a 1.57% share of the overall US generics market, and a top-20 industry ranking. With EBITDA margins at 26.7% and a pipeline of complex generics including Lanreotide (20% market share) and generic Symbicort under review, any reduction in trade barriers strengthens Cipla's already robust supply economics. Aurobindo Pharma (AUROPHARMA) is perhaps the most leveraged to US trade dynamics among Indian generics. US quarterly revenue stands at Rs 3,001 crores (up 9.3% year-on-year), per their latest quarterly results. With 547 approved ANDAs — among the largest portfolios globally — and injectable and specialty sales reaching $150 million, the formulation business contributes roughly 85% of total revenue. Management noted that "revenues are mainly supported by growth across markets of the US, Europe," making the trade deal a safeguard for the company's most critical revenue corridor.

Specialty Chemicals: The Quiet Winner

Aarti Industries (AARTIIND) may be the most interesting play in this trade deal. Management described the US-India trade deal as providing "a sigh of relief" that is "expected to boost the business in the US in coming times," calling it "a structural shift in global trade." The company has seen "resumption of US volumes for MMA and PDCB" and had been partially absorbing tariff costs — meaning tariff reduction flows directly to the bottom line. With an EBITDA margin target of 25-30% and Rs 2,500-3,000 crores in chemical capacity expansion underway at Jhagadia, Aarti is scaling up precisely as the trade environment turns favorable.

Auto Components: Precision Engineering Meets Trade Tailwinds

Sansera Engineering is building an Aerospace, Defense & Space (ADS) business that grew 56.4% year-on-year in Q2 FY26. ADS revenue reached Rs 496 million in a single quarter, with management targeting Rs 3,000-3,200 million annually. Overall revenue grew 8.1% to Rs 8,252 million with EBITDA margins at 17.3%. Following the interim US-India trade deal, management noted that decision-making from OEMs "with respect to production and new order placements" had been on hold due to tariff uncertainties — and that resolution would unlock pent-up demand. The non-auto segment now contributes 14% of sales and is growing faster than the core business.

What Retail Investors Should Do

The India-US trade deal shifts the calculus for every company with significant US export revenue. The clearest near-term beneficiaries are companies that were actively absorbing tariff costs (Aarti Industries, Gokaldas Exports) — their margins should expand as those costs reverse. Companies operating below capacity on US-facing operations (Indo Count Industries) have volume upside. For pharma, the deal reinforces an already strong competitive moat.

Focus on companies where US revenue exceeds 25% of total and where management has explicitly cited trade deal benefits in recent filings. Watch for margin expansion over the next 2-3 quarters. Be cautious, however: trade agreements take time to fully implement, and the tariff landscape remains fluid. Position for the structural trend, not overnight gains.

Data sourced from company filings on NSE via Xaro.